Growing Demand for Organ Transplant to Augment Growth of the Organ Transplant Immunosuppressant Drugs Market
Organ transplant immunosuppressant
drugs are used to minimize the chances of organ rejection after
transplantation. Immunosuppressants are drugs that lower the body's ability to
reject a transplanted organ. These drugs dilute the immune system and help
reduce the reaction towards the transplant. There are two types of
immunosuppressant drugs, such as maintenance drugs and induction drugs. Both
are antirejection drugs. Maintenance drugs are intended to use for long term,
while induction drugs are used during the transplant.
Market Dynamics:
Increasing demand for organ transplant and the growing
number of patients in need of organ transplants is expected to propel the
growth of the organ transplant immunosuppressant drugs market. For instance, according
to the World Health Organization (WHO), every year, around 100,800 solid organ
transplants are performed across the world. Moreover, in 2018, around 36,528
transplants were performed and more than 113,000 people needed transplants as
of January 2019, according to the U.S. Department of Health and Human Services
and the Health Resources & Services Administration (HRSA).
Moreover, the increasing prevalence of chronic ailments,
especially in North America, and technological advancements in organ
transplants are expected to drive the organ
transplant immunosuppressant drugs market growth. According to the Centers
for Disease Control and Prevention, around 85% of older adults have at least
one chronic health condition, and around 60% have at least two chronic
conditions.
Furthermore, increasing approvals of new products are
expected to augment the growth of the organ transplant immunosuppressant drugs market.
For instance, in November 2020, Lupin launched generic immunosuppressant
Tacrolimus capsules in the American market after its alliance partner Concord
Biotech received an approval for the product from the U.S. health regulator.
Competitive Analysis:
Major players operating in the organ transplant
immunosuppressant drugs market are Astellas
Pharma, Novartis AG, Accord Healthcare Ltd., Genzyme Corporation, Hoffman La
Roche, Strides Pharma Global Pvt. Ltd., Panacea Biotec Ltd., Dr. Reddy’s
Laboratories Ltd., Veloxis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd.,
Leo Pharma, Belcher Pharmaceuticals LLC, GlaxoSmithKline Plc., Mylan
Laboratories, and Watson Pharmaceuticals, Inc.
In February 2021, Creative Medical Technology Holdings, Inc.
announced filing of a patent application covering the use of ImmCelz
regenerative cell therapy for preventing rejection of transplanted organs.
In December 2020, Biocon launched Tacrolimus capsules in the
United States. Tacrolimus is an immunosuppressant used in the treatment of organ
transplant patients that reduces the body’s ability to reject a transplanted
organ.

Comments
Post a Comment